40 Years of Topical Tretinoin Use in Review

June 2013 | Volume 12 | Issue 6 | Original Article | 638 | Copyright © June 2013


Hilary E. Baldwin MD,a Marge Nighland BS,b Clare Kendall MA,c David A. Mays PharmD MBA,c Rachel Grossman MD,b,c and Joan Newburger PhDc

aSUNY Downstate Medical Center, Brooklyn, NY bValeant Dermatology, a subsidiary of Valeant Pharmaceuticals North America LLC, Bridgewater, NJ cJohnson & Johnson Consumer & Personal Products Worldwide, Skillman, NJ

  1. Ghali F, Kang S, Leyden J, Shalita AR, Thiboutot DM. Changing the face of acne therapy. Cutis. 2009;83(Suppl 2):4-15.
  2. Atralin [package insert]. Fort Worth, TX: Coria Laboratories, Ltd; 2007.
  3. Webster G, Cargill DI, Quiring J, Vogelson CT, Slade HB. A combined analysis of 2 randomized clinical studies of tretinoin gel 0.05% for the treatment of acne. Cutis. 2009;83(3):146-154.
  4. Berger R, Barba A, Fleischer A, et al. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults. Cutis. 2007;80(2):152-157.
  5. Nighland M, Grossman R. Tretinoin microsphere gel in facial acne vulgaris: a meta-analysis. J Drugs Dermatol. 2008;7(Supp 8):S2-S8.
  6. Kircik LH. Comparative efficacy and safety results of two topical combination acne regimens. J Drugs Dermatol. 2009;8(7):624-630.
  7. Schmidt N, Gans EH. Tretinoin: a review of its anti-inflammatory properties in the treatment of acne. J Clin Aesthet Dermatol. 2011;4(11):22-29.
  8. Veltin [package insert]. Research Triangle Park, NC: Stiefel Laboratories, Inc; 2010.
  9. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol. 2006;54(1):73-81.
  10. Pariser D, Bucko A, Fried R, et al. Tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for treatment of acne vulgaris: morning/morning regimen is as effective and safe as morning/evening regimen. J Drugs Dermatol. 2010;9(7):805-813.
  11. Embil K, Nacht S. The Microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 1996;13(5):575-588.
  12. Nighland M, Yusuf M, Wisniewski S, Huddleston K, Nyirady J. The effect of simulated solar UV irradiation on tretinoin in tretinoin gel microsphere 0.1% and tretinoin gel 0.025%. Cutis. 2006;77(5):313-316.
  13. Nyirady J, Lucas C, Yusuf M, Mignone P, Wisniewski S. The stability of tretinoin in tretinoin gel microsphere 0.1%. Cutis. 2002;70(5):295-298.
  14. Kligman AM, Grove GL, Hirose R, Leyden JJ. Topical tretinoin for photoaged skin. J Am Acad Dermatol. 1986;15(4 Pt 2):836-859.
  15. Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327-348.
  16. Babamiri K, Nassab R. Cosmeceuticals: the evidence behind the retinoids. Aesthet Surg. 2010;30(1):74-77.
  17. Serri R, Iorizzo M. Cosmeceuticals: focus on topical retinoids in photoaging.Clin Dermatol. 2008;26(6):633-635.
  18. Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55(6):1048-1065.
  19. Kimbrough-Green CK, Griffiths CE, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol. 1994;130(6):727-733.
  20. Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol. 2006;54(Suppl 5):S272-S281.
  21. Ting W. Tretinoin for the treatment of photodamaged skin. Cutis. 2010;86(1):47-52.
  22. Leyden JJ, Grossman R, Nighland M. Cumulative irritation potential of topical retinoid formulations. J Drugs Dermatol. 2008;7(Suppl 8):S14-S18.
  23. Skov MJ, Quigley JW, Bucks DA. Topical delivery system for tretinoin: research and clinical implications. J Pharm Sci. 1997;86(10):1138-1143.
  24. Katz KA. Topical tretinoin, lung cancer, and lung-related mortality. Arch Dermatol. 2008;144(7):945-946.
  25. Weinstock MA, Bingham SF, Lew RA, et al. Topical tretinoin therapy and all-cause mortality. Arch Dermatol. 2009;145(1):18-24.
  26. Shapiro S, Heremans A, Mays DA, Martin AL, Hernandez-Medina M, Lanes S. Use of topical tretinoin and the development of noncutaneous adverse events: evidence from a systematic review of the literature. J Am Acad Dermatol. 2011;65(6):1194-1201.
  27. Bozzo P, Chua-Gocheco A, Einarson A. Safety of skin care products during pregnancy. Can Fam Physician. 2011;57(6):665-667.
  28. Camera G, Pregliasco P. Ear malformation in baby born to mother using tretinoin cream. Lancet. 1992;339(8794):687.
  29. Lipson AH, Collins F, Webster WS. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet. 1993;341(8856):1352-1353.
  30. Navarre-Belhassen C, Blanchet P, Hillaire-Buys D, Sarda P, Blayac JP. Multiple congenital malformations associated with topical tretinoin. Ann Pharmacother. 1998;32(4):505-506.
  31. Selcen D, Seidman S, Nigro MA. Otocerebral anomalies associated with topical tretinoin use. Brain Dev. 2000;22(4):218-220.
  32. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet. 1993;341(8854):1181-1182.
  33. Shapiro L, Pastuszak A, Curto G, Koren G. Safety of first-trimester exposure to topical tretinoin: prospective cohort study. Lancet. 1997;350(9085):1143-1144.
  34. Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A. 2005;136(2):117-121.
  35. Latriano L, Tzimas G, Wong F, Wills RJ. The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and its metabolites after single doses or long-term use. J Am Acad Dermatol. 1997;36(3 Pt 2):S37-S46.
  36. Renova (tretinoin cream) 0.02% [package insert]. Los Angeles, CA: Ortho Dermatologics, a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2008.
  37. Bercovitch L. Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-fluorouracil: a double-blind controlled study. Br J Dermatol. 1987;116(4):549-552.
  38. Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009;115(11):2523-2530.
  39. Lee K, Weinstock M. Prospective quality of life impact of actinic keratoses: observations from the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Acta Derm Venereol. 2011;91(1):101-102.
  40. Lee KC, Weinstock MA; Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) Trial Group. Prospective quality of life impact of keratinocyte carcinomas: observations from the Veterans Affairs Topical Tretinoin Chemoprevention Trial. J Am Acad Dermatol. 2010;63(6):1107-1109.
  41. Misiewicz J, Sendagorta E, Golebiowska A, Lorenc B, Czarnetzki BM, Jablonska S. Topical treatment of multiple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: a double-blind, comparative study. J Am Acad Dermatol. 1991;24(3):448-451.
  42. Weinstock MA, Lee KC, Chren MM, Marcolivio K; VATTC Trial Group. Quality of life in the actinic neoplasia syndrome: the VA Topical Tretinoin Chemoprevention (VATTC) Trial. J Am Acad Dermatol. 2009;61(2):207-215.
  43. Weinstock MA, Bingham SF, Cole GW, et al. Reliability of counting actinic keratoses before and after brief consensus discussion: the VA topical tretinoin chemoprevention (VATTC) trial. Arch Dermatol. 2001;137(8):1055-1058.
  44. Griffiths CE. The role of retinoids in the prevention and repair of aged and photoaged skin. Clin Exp Dermatol. 2001;26(7):613-618.
  45. Prystowsky JH. Topical retinoids. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001;578-594.
  46. Rivers JK, McArdle CA, Gupta G, McCarthy SW, O’Brien CJ, McCarthy WH. Recurrent melanoma after topical tretinoin. Lancet. 1989;2(8676):1393.
  47. Stam-Posthuma JJ, Vink J, le Cessie S, Bruijn JA, Bergman W, Pavel S. Effect of topical tretinoin under occlusion on atypical naevi. Melanoma Res. 1998;8(6):539-548.
  48. Edwards L, Jaffe P. The effect of topical tretinoin on dysplastic nevi. A preliminary trial. Arch Dermatol. 1990;126(4):494-499.
  49. Halpern AC, Schuchter LM, Elder DE, et al. Effects of topical tretinoin on dysplastic nevi. J Clin Oncol. 1994;12(5):1028-1035.
  50. Meyskens FL Jr, Edwards L, Levine NS. Role of topical tretinoin in melanoma and dysplastic nevi. J Am Acad Dermatol. 1986;15(4 Pt 2):822-825.
  51. Rivers JK, McCarthy WH. No effect of topical tretinoin on lentigo maligna. Arch Dermatol. 1991;127(1):129.
  52. Zhang H, Rosdahl I. Expression profiles of p53, p21, bax and bcl-2 proteins in all-trans-retinoic acid treated primary and metastatic melanoma cells. Int J Oncol. 2004;25(2):303-308.
  53. Ash K, Lord J, Zukowski M, McDaniel DH. Comparison of topical therapy for striae alba (20% glycolic acid/0.05% tretinoin versus 20% glycolic acid/10% L-ascorbic acid). Dermatol Surg. 1998;24(8):849-856.
  54. Elson ML. Treatment of striae distensae with topical tretinoin. J Dermatol Surg Oncol. 1990;16(3):267-270.
  55. Har-Shai Y, Barak A, Taran A, Weissman A. Striae distensae of augmented breasts after oral contraceptive therapy. Ann Plast Surg. 1999;42(2):193-195.
  56. Kang S, Kim KJ, Griffiths CE, et al. Topical tretinoin (retinoic acid) improves early stretch marks. Arch Dermatol. 1996;132(5):519-526.
  57. Pribanich S, Simpson FG, Held B, Yarbrough CL, White SN. Low-dose tretinoin does not improve striae distensae: a double-blind, placebo-controlled study. Cutis. 1994;54(2):121-124.
  58. Rangel O, Arias I, García E, Lopez-Padilla S. Topical tretinoin 0.1% for pregnancy-related abdominal striae: an open-label, multicenter, prospective study. Adv Ther. 2001;18(4):181-186.
  59. Ruffin MT, Bailey JM, Normolle DP, et al. Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2148-2152.
  60. Graham V, Surwit ES, Weiner S, Meyskens FL Jr. Phase II trial of β-all-trans-retinoic acid for cervical intraepithelial neoplasia delivered via a collagen sponge and cervical cap. West J Med. 1986;145(2):192-195.
Close Menu